search

Active clinical trials for "Liver Diseases"

Results 1181-1190 of 1972

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

Hepatic ImpairmentHealthy Volunteers

The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961

Completed19 enrollment criteria

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Moderate Hepatic ImpairmentSevere Hepatic Impairment1 more

This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with hepatic impairment and healthy adults.

Completed29 enrollment criteria

Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury

Liver DiseaseImpaired Liver Function1 more

This study is being done to determine if an investigational study drug called Omegaven can help to improve liver disease thought to be caused by Total Parenteral Nutrition (TPN). TPN is intravenous feeding (IV feeding tube) that provides patients the nutrients when they are unable to drink fluid or eat food by mouth.

Completed17 enrollment criteria

Hepatic Impairment Trial of Obeticholic Acid

Hepatic Impairment

This is a phase 1 study to evaluate the safety of a single 10 mg dose of obeticholic acid (OCA) in healthy volunteers and patients with liver disease.

Completed40 enrollment criteria

A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection

Nonalcoholic Fatty Liver DiseaseHepatic Steatosis1 more

The purpose of this study is to measure the effect of a short-term low calorie diet on patients with a Body Mass Index (BMI) over 25 who are undergoing liver surgery.

Completed7 enrollment criteria

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared...

Hepatic Impairment

This study aims to determine the pharmacokinetic profile and the tolerability of iloperidone in subjects with mild or moderate hepatic impairment comparatively to healthy matched subjects

Completed13 enrollment criteria

A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941

Liver Disease

The purpose of this study is to evaluate the pharmacokinetics (PK) and safety following oral administration of ASP1941 in subjects with moderate hepatic impairment and in subjects with normal hepatic function based on the Child-Pugh Classification (CPC).

Completed23 enrollment criteria

Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and...

Liver DiseasesHepatic Encephalopathy1 more

The purpose of this study is to determine whether Branched chain Amino Acids enhances the uptake of ammonia in muscle tissue.

Completed4 enrollment criteria

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal...

Hepatic Impairment

The purpose of this international study was to assess the effect of varying degrees of impaired hepatic function compared to a normal hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of midostaurin.

Completed32 enrollment criteria

Effects of Fructose Restriction on Liver Steatosis

Nonalcoholic Fatty Liver DiseaseGlucose Metabolism Disorders1 more

Nonalcoholic fatty liver disease (NAFLD) is an emerging health problem as it can lead to end stage liver failure and cardiovascular complications. Diet play an important role in the development of NAFLD. Many studies have addressed the effects of added fructose on NAFLD. To date, little attention has been paid to the effects of a diet devoid of fructose. Therefore, the investigators aim to study the effects of fructose restriction on hepatic fat accumulation and vascular function using a double-blind randomized placebo-controlled design.

Completed13 enrollment criteria
1...118119120...198

Need Help? Contact our team!


We'll reach out to this number within 24 hrs